Chinese Journal of Hospital Pharmacy

Efficacy and safety of chemoradiotherapy sequencing on rectal cancer in total neoadjuvant therapy： a systematic review and network Meta-analysis

WANG Zichen, XU Shuna, WANG Jinmeng, REN Yanling, LI Weihua, DI Huifeng

Chinese Journal of Hospital Pharmacy, 2024, 44(1): 79-87. DOI: 10.13286/j.1001-5213.2024.01.12

作者姓名及年份	队列选择				可比性	结果
作者姓名及年份	暴露队列的代表性	非暴露队列的代表性	暴露的确定	研究对象是否已经发生疾病	暴露与非暴露队列的可比性	结果测定方法	随访时间是否足够长	随访完整性	分数
Calvo等2014^[13]	★	★	★	★	★		★		6
Cercek等2018^[14]	★	★	★	★	★★	★			7
Zhai等2020^[18]	★	★	★	★	★	★			6

Tab 4 Newcastle-Ottawa scale

Other figure/table from this article

Tab 1 Search strategy of PubMed database
Tab 2 Protocols of neoadjuvant therapy
Fig 1 Flow chart of literature screening
Tab 3 Basic characteristics of the included studies
Fig 2 Evaluation results of risk of bias
Fig 3 Network plots of each endpoint for each therapy model 注（note）：病理完全缓解（pathological complete response rate， pCRR）；不良事件发生率（adverse effects rate，AEsR）；总生存期（overall survival， OS）；无病生存期（disease free survival， DFS）。
Tab 5 SUCRA of each regimen with regard to all outcomes for each therapy model
Fig 4 Odds ratio （OR） and 95%CI of all regimens from network Meta-analysis for six indicators 注（note）：中间深色板块将联赛表分为上下两部分，OR（odds ratio）值代表列与行两方案的比值比［different interventions in the middle blocle divded the graph into upper and lower triangle；the OR （odds ratio） value represents the odds ratio of the two prototocols in the column and row］；95%CI 不包括1.00代表两方案有显著性差异，用灰色方块表示，且加粗标有星号（95%CI excluding 1.00 means there is a significant difference between the two protocols and is represented by a gray square with a bold asterisk）。
Tab 6 Comparison of adverse events between regimens E and F
Fig 5 Bias funnel plots for six outcome indicators